Takeaway

• First-line immunotherapy with atezolizumab led to significant survival benefits compared to chemotherapy in unfit patients with advanced/metastatic non-small-cell lung cancer (NSCLC) who were ineligible for platinum-based regimens.
• Benefits were independent of PD-L1 status, performance status, and histology.
• QoL was maintained and no new safety signals emerged.

Why this matters...